Vaccination for pandemic influenza: A six point agenda for interpandemic years

Pediatric Infectious Disease Journal

Volumn 23, Issue 1 SUPPL., 2004, Pages

  Fedson, David S ^a   Monto, Arnold S ^b  

^a Pasteur Merieux Connaught   (France)

^b NONE

Author keywords

Global registration; Influenza; Pandemic; Vaccine

Indexed keywords

INFLUENZA VACCINE;

COMPARATIVE STUDY; CONFERENCE PAPER; DRUG MARKETING; DRUG USE; ECONOMIC ASPECT; EPIDEMIC; EPIDEMIOLOGICAL DATA; FEMALE; GENETIC ENGINEERING; HEALTH; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MALE; POLITICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SENSITIVITY AND SPECIFICITY; SKILL; STANDARD; TREATMENT PLANNING; VACCINATION; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION;

EID: 0842284591     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000108195.12141.cc     Document Type: Conference Paper

References (11)

1. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines, Vaccine 2003;21:1769-75.
2. Van Essen GA, Palache AM, Forleo E, Fedson DS, Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine 2003;16:1780-5.
3. Hilleman MR. Cooperation between government and industry in combating a perceived emerging pandemic: the 1976 Swine Influenza Vaccination Program. JAMA 1996;275:241-3.
4. Fedson DS, Pandemic influenza and the global vaccine supply. Clin Infect Dis 2003;36:1552-61.
5. Wood JM. Developing vaccines against pandemic influenza. Phil Trans R Soc Lond B Biol Sci 2001;356:1953-60.
6. Neumann G, Kawaoka Y. Reverse genetics of influenza virus. Virology 2001;287:243-60.
7. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF-59 adjuvanted A/Duck/Singapore/97 (H5N3) vaccine: a randomized trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937-43.
8. Hehme N, Engelmann H, Kunzel W, Neumeier E, Sanger R. Pandemic preparedness: lessons learned from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol (Berl) 2002;191:203-8.
9. Wood JM, Lewandowski RA. The influenza vaccine licensing process. Vaccine 2003;16:1786-8.
10. Shabas RE. Mass influenza vaccination in Ontario: a sensible move. Can Med Assoc J 2001;164:36-7.
11. Fifty-sixth World Health Assembly. May 19 to 23, 2003. Influenza. Report by the Secretariat (A56/23). Available at: http://www.who.int/gb/. Accessed September 17, 2003.